News

Filter

Current filters:

StivargaSanofi

1 to 9 of 97184 results

Lundbeck to stop further development of desmoteplase

Lundbeck to stop further development of desmoteplase

18-12-2014

Following evaluation of disappointing clinical results, Danish CNS specialists Lundbeck said late yesterday…

Cardio-vasculardesmoteplaseFinancialLundbeckNeurologicalPharmaceuticalResearch

Auspex leaps on positive results from Phase III trial of SD-809 in Huntington's chorea

Auspex leaps on positive results from Phase III trial of SD-809 in Huntington's chorea

17-12-2014

Movement disorder biopharma specialist Auspex Pharmaceuticals announced positive top-line data from its…

Auspex PharmaceuticalsNeurologicalPharmaceuticalResearchSD-809USA

Strong top-line results for Poxel’s antidiabetic agent imeglimin

Strong top-line results for Poxel’s antidiabetic agent imeglimin

17-12-2014

France-based drug developer Poxel says that imeglimin, a novel compound in development to treat type…

DiabetesFranceHealthimegliminMerck SeronoPharmaceuticalPoxelResearch

KCR acquires project portfolio from Ukraine’s CRO AXIS

KCR acquires project portfolio from Ukraine’s CRO AXIS

17-12-2014

KCR, a Poland-based contract research organization (CRO), has recently acquired the whole portfolio of…

AXIS GroupKCRMergers & AcquisitionsPharmaceuticalResearchUkraine

Ipsen appoints François Garnier as executive vice president, general counsel

Ipsen appoints François Garnier as executive vice president, general counsel

17-12-2014

French drugmaker Ipsen has appointed François Garnier as executive vice president, general counsel of…

BoardroomFranceIpsenIpsen GroupPharmaceutical

New guidance provides optimism for securing life sciences patents in USA

New guidance provides optimism for securing life sciences patents in USA

17-12-2014

The US Patent and Trademark Office (USPTO) has released its 2014 Interim Guidance on Patent Subject Matter…

PatentsPharmaceuticalPrometheus LabsUS Patent and Trademark OfficeUSA

1 to 9 of 97184 results

Back to top